(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection. - 2'Weezer: The Gathering' 2026 tour: How to get tickets, prices, dates and more
- 3How Would You Like to Deal with Your Funds?
- 4Israel strikes Iranian nuclear development facilities, Tehran vows retaliation
- 5If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving
- New Jordan security fence could be done in early 2028
- Trump signs a law returning whole milk to school lunches
- American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- Internet Bookkeeping Programming for Consultants
- Los Angeles County sees significant uptick in norovirus cases, officials say
- Creative Style: 10 Architects Reclassifying the Business
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Vote in favor of Your #1 BWM Vehicles
